Department of Cardiology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Medicine (Baltimore). 2024 Nov 1;103(44):e39927. doi: 10.1097/MD.0000000000039927.
Qishen Yiqi dropping pills combined with modern medicine have been widely used as a treatment for coronary heart disease with ischemic heart failure. Currently, there have been no robust studies addressing the efficacy and safety of Qishen Yiqi dropping pills combined with modern medicine for coronary heart disease with ischemic heart failure. Therefore, this systematic review and meta-analysis are conducted to fill in the gaps mentioned above.
This systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Relevant studies published from inception to April 17, 2023, in the 5 electronic databases: PubMed, The Cochrane Library, EMBASE, CNKI, and the Wanfang database were comprehensively searched. Weighted mean difference was used as the effect size for the continuous variables. Pooled odd ratios are presented if the results are binary variables. Additionally, we performed subgroup and sensitivity analyses to examine the source of heterogeneity. The funnel plot and the Egger test were used to estimate publication bias.
This meta-analysis included 46 studies involving 5843 participants. There is a significant difference in clinical efficacy, the 6-minute walk test (weighted mean difference = 50.10; 95% CI 28.19 to 72.02; I2 = 98.9%, P = .000), the indexes of ultrasonic cardiogram, blood biochemical indexes, and adverse effects (odds ratios = 0.46; 95% CI 0.29 to 0.75; I2 = 35.9%, P = .142). The sensitivity analysis and publication bias have demonstrated the robustness of the results (P = .702).
Qishen Yiqi dropping pills combined with modern medicine could significantly improve clinical efficacy without incasement adverse effects. Further studies are required to identify the more comprise efficacy and safety results.
芪参益气滴丸联合现代医学已广泛用于治疗冠心病合并缺血性心力衰竭。目前，还没有关于芪参益气滴丸联合现代医学治疗冠心病合并缺血性心力衰竭的疗效和安全性的稳健研究。因此，进行了这项系统评价和荟萃分析，以填补上述空白。
本系统评价按照系统评价和荟萃分析的首选报告项目进行，并进行了报告。从成立到 2023 年 4 月 17 日，全面搜索了 5 个电子数据库：PubMed、The Cochrane Library、EMBASE、CNKI 和万方数据库中发表的相关研究。对于连续变量，使用加权均数差作为效应量。如果结果是二项变量，则呈现合并的优势比。此外，我们进行了亚组和敏感性分析，以检查异质性的来源。使用漏斗图和 Egger 检验估计发表偏倚。
这项荟萃分析包括 46 项研究，涉及 5843 名参与者。在临床疗效、6 分钟步行试验（加权均数差=50.10；95%CI 28.19 至 72.02；I2=98.9%，P=.000）、超声心动图指标、血液生化指标和不良反应（优势比=0.46；95%CI 0.29 至 0.75；I2=35.9%，P=.142）方面存在显著差异。敏感性分析和发表偏倚表明结果具有稳健性（P=.702）。
芪参益气滴丸联合现代医学可显著提高临床疗效，且不良反应发生率无增加。需要进一步研究以确定更全面的疗效和安全性结果。
